This bill aims to enhance access to health care by prohibiting prior authorization requirements for certain medications prescribed for antineoplastic cancer treatment and ensuring that prior authorization denials cannot be based on the timing of health care services provided. Specifically, it amends Minnesota Statutes 2024, section 62M.07, to include provisions that require expedited prior authorization reviews for medications that have been previously authorized or covered. The bill also introduces a new subdivision that mandates utilization review organizations, health plan companies, and claims administrators to process prior authorizations for medications that have been previously authorized for a patient, ensuring continuity of care.

Key amendments include the removal of the requirement for prior authorization for antineoplastic cancer treatment medications, which must now align with nationally accepted standards of care. Additionally, the bill stipulates that prior authorization requests must be accepted for review within seven days of the health care service being provided, and it prohibits denials based on the timing of requests. These changes are designed to streamline the authorization process and improve patient access to necessary medications and treatments.

Statutes affected:
Introduction: 62M.07